10/816,298

* * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:05:12 ON 14 DEC 2006

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 20:05:29 ON 14 DEC 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5
DICTIONARY FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

*** YOU HAVE NEW MAIL ***

=>
Uploading C:\Program Files\Stnexp\Queries\10816298.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 20:05:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3826866 TO ITERATE

```
 24.2% PROCESSED   926147 ITERATIONS                          17385 ANSWERS

 26.1% PROCESSED  1000000 ITERATIONS                          19421 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.20

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      3826866 TO  3826866
PROJECTED ANSWERS:           73504 TO    75138

L2        19421 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'CAPLUS' ENTERED AT 20:06:19 ON 14 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Dec 2006  VOL 145 ISS 25
FILE LAST UPDATED: 13 Dec 2006  (20061213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3        1226 L2

=> s l3 and label (8a) base
         62877 LABEL
        689309 BASE
           358 LABEL (8A) BASE
L4           1 L3 AND LABEL (8A) BASE

=> d l4 bib abs hitstr

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:837304  CAPLUS
DN   141:296250
TI   Preparation of nucleotide analogs with six membered rings and their
     incorporation into nucleic acids
IN   Bergmann, Frank; Donner, Horst; Von der Eltz, Herbert; Heindl, Dieter;
     Herdewijn, Piet
PA   Roche Diagnostics G.m.b.H., Germany; F.Hoffmann-La Roche A.-G.
SO   Eur. Pat. Appl., 44 pp.
     CODEN: EPXXDW
DT   Patent
```

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1466919	A1	20041013	EP 2004-7907	20040401
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CA 2463719	AA	20041005	CA 2004-2463719	20040331
	US 2005004078	A1	20050106	US 2004-816298	20040401
	JP 2004339202	A2	20041202	JP 2004-110224	20040402
	CN 1569870	A	20050126	CN 2004-10045158	20040405
PRAI	EP 2003-7844	A	20030405		

OS MARPAT 141:296250
GI



I

AB Title compds. (I; L = linker; B = heterocyclic base; R1 = protecting group, label solid phase, H; R2 = H, OR6; R3 = protecting group, linker covalently coupled to a solid phase, phosphoramidite, phosphonate, triphosphate; R4 = H, OH, alkyl, halo, OR5, SR5, NR5R5a, label linker covalently coupled to a solid phase; R6 = H, protecting group, linking moiety coupled to a solid phase, phosphoramidite, phosphonate; R5 = alkyl, alkenyl, alkynyl, aryl, acyl, protecting group, H; R5a, R5b = H, alkyl, alkenyl, alkynyl, aryl, acyl; Y = O, S, NR5, CR5aR5b; dotted line = optional double bond), were prepared Thus, 1,5-anhydro-2-(5-(6-biotin-amido-hexanoate amido-allyl)-uracil)-2,3-dideoxy-D-arabino-hexitol-6-triphosphate was prepared for incorporation into nucleic acids for use in PCR (polymerase chain reaction)-based diagnostics.

IT 764657-94-5P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of labeled nucleotides, capable of oligomerization, for uses in nucleic acid hybridization and PCR diagnostic studies)

RN 764657-94-5 CAPLUS
CN D-arabino-Hexitol, 6-O-[bis(4-methoxyphenyl)phenylmethyl]-1,5-anhydro-2,3-dideoxy-2-[5-[3-[[6-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]hexyl]amino]-3-oxo-1-propenyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]-, 4-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



IT 764657-93-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of labeled nucleotides, capable of oligomerization, for uses in nucleic acid hybridization and PCR diagnostic studies)

RN 764657-93-4 CAPLUS

CN D-arabino-Hexitol, 6-O-[bis(4-methoxyphenyl)phenylmethyl]-1,5-anhydro-2,3-dideoxy-2-[5-[3-[[6-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]hexyl]amino]-3-oxo-1-propenyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



```
=> d his

     (FILE 'HOME' ENTERED AT 20:05:12 ON 14 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 20:05:29 ON 14 DEC 2006
L1             STRUCTURE UPLOADED
L2         19421 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 20:06:19 ON 14 DEC 2006
L3          1226 S L2
L4             1 S L3 AND LABEL (8A) BASE

=> s 3 and label?
       6758686 3
        442428 LABEL?
L5      148199 3 AND LABEL?

=> s l3 and label? (10a) base
        442428 LABEL?
        689309 BASE
          1953 LABEL? (10A) BASE
L6           1 L3 AND LABEL? (10A) BASE

=> s 16 not 15
```

```
L7            0 L6 NOT L5

=> s l3 and label?
         442428 LABEL?
L8           15 L3 AND LABEL?

=> s l8 not l6
L9           14 L8 NOT L6

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10          14 DUP REM L9 (0 DUPLICATES REMOVED)

=> d l10 bib abs 1-14

L10  ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2006:699763  CAPLUS
DN   145:145535
TI   Preparation of 11C-labeled benzyl-lactam compounds and their use
     as imaging agents
IN   Helal, Christopher John; Antoni, Gunnar; Langstrom, Bengt; Sheng, Jia Zhi;
     Jaynes-Sobolove, Susan Beth; McCarthy, Timothy John
PA   Pfizer Products Inc., USA
SO   PCT Int. Appl., 36 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2006075226        A1    20060720    WO 2006-IB28            20060111
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRAI US 2005-643453P      P     20050113
OS   MARPAT 145:145535
GI
```



```
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *
```


AB The invention relates to 11C-labeled compds. I [X = CH or N; Y = C(OR1)(R2)2 or N(R3)2; R1 = H or alkyl; R2 independently = alkyl or both R2 groups together form (CH2)n where n = 2-7; R3 independently = alkyl or both groups together form (CH2)O(CH2)2, (CH2)(NR4)(CH2)2, or (CH2)m where m = 2-7; R4 = H or Me; * signifies a chiral carbon, wherein the carbon is a racemate, an (R)-enantiomer, an (S)-enantiomer, or a mixture thereof], their preparation, compns. comprising an effective amount of a 11C-labeled compound, and the use of a "C-labeled compound as a radiopharmaceutical for positron emission tomog. Thus, e.g., II was prepared by resolution of 1-[4-(1-methoxy-1-methylethyl)phenyl]-3-(2-piperazin-1-yl)pyrrolidin-2-one (preparation given) to the (R)-enantiomer followed by N-methylation with 11CH3I.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:366881 CAPLUS
DN 144:412478
TI Preparation of pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds as ligands of C5a receptors
IN Yuan, Jun; Hrnciar, Peter; Guo, Qin; Maynard, George D.
PA Neurogen Corporation, USA
SO PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006042102	A2	20060420	WO 2005-US36126	20051005

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-616311P P 20041005
OS MARPAT 144:412478
GI



I



II

AB The title compds. I [E = a bond, O, SOm, NR6, CR6R7; R6, R7 = H, alkyl; m = 0-2; Ar = (un)substituted Ph, 1- and 2-naphthyl, heteroaryl; 5-membered ring containing Z1 and Z2 atoms contains exactly one heteroatom; Z1 = CR1 or NR11; Z3 = CR3, NR31; R1, R11 = alkyl, cycloalkyl, aryl, etc.; R2 = H, halo, OH, etc.; R3, R31 = alkyl, haloalkyl, alkoxy, etc.; Z4 = NR, CR4; R is absent or oxygen; R4, R5 = H, halo, OH, etc.] which are ligands of C5a receptors, were prepared and formulated. E.g., a 2-step synthesis of II, starting from 2-chloro-4-methyl-5-nitropyridine and 2,6-diethylphenylboronic acid, was given. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compds. of the invention (I) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compns. comprising such compds. I, and to the use of such compds. in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compds., which are useful as probes for the localization of C5a receptors.

L10 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:164346 CAPLUS
DN 144:234605
TI Fluorescein fluorescent labeling agents
IN Nagano, Tetsuo; Urano, Yasuteru; Mineno, Tomoko; Ueno, Tasuku
PA Daiichi Pure Chemicals Co., Ltd., Japan
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006019105	A1	20060223	WO 2005-JP14983	20050817

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-601986P P 20040817
OS MARPAT 144:234605
GI



I

AB The fluorescent labeling agent exhibiting high fluorescence in a state bound to the substrate to be labeled, contains I (R1-4 = H, a monovalent substituent; R5 = H, a monovalent group exclusive of carboxy and sulfo; R6, R7 = H, halo; and R8 = H, alkylcarbonyl, alkylcarbonyloxymethyl) bonded with a labeling compound
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:1001055 CAPLUS
TI Synthesis of new, BODIPY-based sensors and labels
AU Kalai, Tamas; Hideg, Kalman
CS Institute of Organic and Medicinal Chemistry, University of Pecs, Pecs, H-7602, Hung.
SO Tetrahedron (2006), 62(44), 10352-10360
CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier Ltd.
DT Journal
LA English
AB New, 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dye based thiol-reactive fluorescent label, fluorescent amino acid, and fluoroionophore compds. with 540-560 nm emission are described. Combination of a BODIPY dye with a nitronyl nitroxide or an imino nitroxide or a bifunctional pyrroline nitroxide furnished a nitric oxide, a redox sensitive mol. and a double (spin and fluorescence) label , resp.
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:660686 CAPLUS
DN 145:284874
TI Synthesis of Trifluoromethylaryl Diazirine and Benzophenone Derivatives of Etomidate that Are Potent General Anesthetics and Effective Photolabels for Probing Sites on Ligand-Gated Ion Channels
AU Husain, S. Shaukat; Nirthanan, Selvanayagam; Ruesch, Dirk; Solt, Ken; Cheng, Qi; Li, Guo-Dong; Arevalo, Enrique; Olsen, Richard W.; Raines, Douglas E.; Forman, Stuart A.; Cohen, Jonathan B.; Miller, Keith W.
CS Department of Anesthesia and Critical Care, Massachusetts General Hospital, Boston, MA, 02114, USA
SO Journal of Medicinal Chemistry (2006), 49(16), 4818-4825
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI



I



II

AB To locate the binding sites of general anesthetics on ligand-gated ion channels, two derivs. of the i.v. general anesthetic etomidate (2-Et 1-(phenylethyl)-1H-imidazole-5-carboxylate), in which the 2-Et group has been replaced by photoactivable groups based on either aryl diazirine or benzophenone chemical, have been synthesized and characterized pharmacol. TDBzl-etomidate (I) and BzBzl-etomidate (II) are both potent general anesthetics with half-effective anesthetic concns. of 700 and 220 nM, resp. Both agents resembled etomidate in enhancing currents elicited by low concns. of GABA on heterologously expressed GABAA receptors and in

shifting the GABA concentration-response curve to lower concns. They also allosterically enhanced the binding of flunitrazepam to mammalian brain GABAA receptors. Both agents were also effective and selective photolabels, photoincorporating into some, but not all, subunits of the Torpedo nicotinic acetylcholine receptor to a degree that was allosterically regulated by an agonist or a noncompetitive inhibitor. Thus, they have the necessary pharmacol. and photochem. properties to be useful in identifying the site of etomidate-induced anesthesia.
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:453922 CAPLUS
DN 145:117200
TI Design and synthesis of a biotin-tagged photoaffinity probe of paeoniflorin
AU Qiu, Wen-Wei; Xu, Jie; Liu, Da-Zhi; Li, Jing-Ya; Ye, Yang; Zhu, Xing-Zu; Li, Jia; Nan, Fa-Jun
CS Chinese National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Shanghai, 201203, Peop. Rep. China
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3306-3309
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 145:117200
AB A trifunctional probe (binding element-photoreactive group-affinity tag) of natural product paeoniflorin was designed and synthesized based on the previous primary structure-activity relationship. This new probe is a potential tool for labeling, purification, and identification of the target proteins.
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:34510 CAPLUS
DN 142:116014
TI Fluorophore compounds and their use in labeling biomolecules and biological structures
IN Moerner, William E.; Twieg, Robert J.; Kline, Douglas W.; He, Meng
PA Stanford University, USA
SO U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005009109	A1	20050113	US 2003-604282	20030708
	WO 2005005956	A2	20050120	WO 2004-US19825	20040621
	WO 2005005956	A3	20050519		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-604282 A 20030708

OS MARPAT 142:116014
AB Fluorophore compds. and methods for their use are disclosed. The fluorophores contain a 2-dicyanomethylen-3-cyano-2,5-dihydrofuran (DCDHF) moiety and one or more donor groups conjugated to the 2-dicyanomethylen-3-cyano-2,5-dihydrofuran group (e.g., 3-cyano-2-dicyanomethylen-4-[4-(N,N-dihexylaminophenyl)]-5,5-dimethyl-2,5-dihydrofuran, DCDHF-6). The donor groups can contain atoms with free electron pairs such as oxygen, sulfur, nitrogen, or phosphorous. The fluorophore compds. can be used to label and detect biol. mols. and biol. structures either in vivo or in vitro.

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1045033 CAPLUS
DN 143:341743
TI Development of novel synthetic substrates for N-acetylglucosamine transferase V
IN Saji, Hideo; Mukai, Takahiro; Magata, Yasuhiro; Node, Satoru; Kato, Takahiro; Taniguchi, Naoyuki; Miyoshi, Hidetomo
PA Nihon Mediphysics Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005263691	A2	20050929	JP 2004-78510	20040318
PRAI JP 2004-78510		20040318		

OS MARPAT 143:341743
GI



I

AB A group of novel radio-labeled substrates that can be working as glyco-chain-receptors for N-acetylglucosamine transferase V has been designed for the rapid and sensitive assay for the enzyme. The synthetic substrates in the group present general equation I (R1 .apprx. R3 are independently hydrogen, halogen or acetyl group and n = integer selectable among the nos. from 2 to 7, and isotope indicator X = 123I, 124I, 131I or most typically 125I). A substrate, IPGMG [2-(4-iodophenyl)ethyl-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→2)-O-α-D-mannopyranosyl-(1→6)-β-D-glucopyranoside] and its enzyme product IPGGMG were synthesized and the usefulness of IPGMG as the substrate for N-acetylglucosamine transferase V was exptl. demonstrated.

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:614646 CAPLUS
DN 143:281936
TI Detection of 210kDa receptor protein for a leaf-movement factor by using novel photoaffinity probes
AU Fujii, Tomohiko; Manabe, Yoshiyuki; Sugimoto, Takanori; Ueda, Minoru
CS Department of Chemistry, Tohoku University, Aoba-ku, Sendai, 980-8578, Japan
SO Tetrahedron (2005), 61(33), 7874-7893
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier B.V.
DT Journal
LA English
AB Circadian rhythmic plant leaf-movement, called nyctinasty, is controlled by a time-course change in the internal concentration of the leaf-movement factor in the plant body. The authors revealed that specific binding proteins (210 and 180 kDa) for the leaf-movement factor, potassium lespedezate, are contained in the plasma membrane of the plant motor cell by using novel synthetic photoaffinity probes. These proteins are localized on the motor cell in the plant body, and would be potential receptors for the leaf-movement factor to control the leaf-movement. The authors' study is a rare successful result of the detection of membrane receptors by using a synthetic photoaffinity probe designed on a biol. active natural product. And these results also advance a guideline for probe design towards successful photoaffinity labeling.
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:502326 CAPLUS
DN 144:36456
TI Development of highly potent D-glucosamine-based chiral fluorescent labeling reagents and a microwave-assisted β-selective glycosidation of a methyl glycoside reagent
AU Ohrui, Hiroshi; Kato, Rumiko; Kodaira, Teruhisa; Shimizu, Hiroki; Akasaka, Kazuaki; Kitahara, Takeshi
CS Graduate School of Life Sciences, Tohoku University, Sendai, 981-8555, Japan
SO Bioscience, Biotechnology, and Biochemistry (2005), 69(5), 1054-1057
CODEN: BBBIEJ; ISSN: 0916-8451
PB Japan Society for Bioscience, Biotechnology, and Agrochemistry
DT Journal
LA English
OS CASREACT 144:36456
AB New chiral fluorescence labeling reagents having a 2,3-anthracenedicarboximide group from D-glucosamine were synthesized, and it was possible to introduce target alcs. at the anomeric positions of the reagents with β-selectivity by glycosidation. Especially, it was possible to use Me glycoside reagent as a glycosyl donor with a Lewis acid and microwave irradiation, and it gave selectively β-glycoside while the reaction without microwave irradiation gave α- and β-mixed glycosides. Those reagents showed very high chiral discrimination ability, and they made it possible to sep. the eight stereoisomers of 4,8,12,16-tetramethylheptadecanol by HPLC after derivatization.
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:428911 CAPLUS
DN 141:7028
TI Preparation of 3-substituted-6-aryl pyridines ligands of C5a receptors
IN Hutchison, Alan; Yuan, Jun; Lee, Kyungae; Maynard, George; Chenard,

Bertrand L.; Liu, Nian; Guo, Qin; Guo, Zihong; Hrnciar, Peter

PA Neurogen Corporation, USA

SO PCT Int. Appl., 366 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043925	A2	20040527	WO 2003-US35694	20031107
	WO 2004043925	A3	20040805		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2504941	AA	20040527	CA 2003-2504941	20031107
	AU 2003291403	A1	20040603	AU 2003-291403	20031107
	US 2004158067	A1	20040812	US 2003-704364	20031107
	EP 1565452	A2	20050824	EP 2003-768799	20031107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-425281P	P	20021108		
	WO 2003-US35694	W	20031107		

OS MARPAT 141:7028

GI



I



II

AB The title compds. [I; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; A = OR4, NR4R5, CR6R7, CHR6R7; R1 = H, halo, NH2, CN, etc.; R2 = halo, CN, XR; R3 = H, halo, OH, etc.; R4 = alkyl, alkenyl, benzoisothiazolyl, etc.; R5 = H, alkyl, alkenyl, etc.; R6 = halo, OH, CN, etc.; R7 = H, halo, OH, etc.; R8 = H, halo, OH, etc.; R9 = absent, H, halo, OH, etc.; X = a bond, O, CO, etc.; R = H, alkyl, alkenyl, etc.; R17 = absent, O] which bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors, and therefore are useful in treating a variety of inflammatory, cardiovascular, and immune system disorders, were prepared and formulated. E.g., a multi-step synthesis of II is given. In

addition, the present invention provides labeled 3-substituted-6-aryl pyridines I, which are useful as probes for the localization of C5a receptors.

L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1031107 CAPLUS
DN 142:6752
TI Synthesis of isotope-coded affinity tags containing a carbohydrate linker group and their use for protein analysis
IN Lockhoff, Oswald; Schumacher, Andreas; Lerchen, Hans-Georg; Immler, Dorian
PA Bayer Healthcare A.-G., Germany
SO Ger. Offen., 39 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10322077	A1	20041202	DE 2003-10322077	20030515
PRAI DE 2003-10322077		20030515		

OS MARPAT 142:6752
GI



I

AB The invention concerns isotope-coded affinity markers, e.g. (I), containing a carbohydrate group(s) as linker between an affinity portion of the mol. and a label portion, for mass-spectrometric anal. of proteins, their production, use and kits containing them. Selected segments of the mol. can contain isotopic atoms, e.g.13C in the carbohydrate or its alkyl link to the affinity group. Thus, biotin was reacted with 4-hydroxybenzaldehyde to form the left portion of I. To form the right portion of I, 2,3,4,6-tetra-O-acetyl-β-D-glucopyranose was reacted with acetonitrile, reduced to the free amine, and reacted with maleic acid anhydride. The left and right intermediates were then reacted to give I. Preparation of 2-bromoethyl β-D-gluco-13C6-pyranoside from β-D-glucopyranose-13C6 pentaacetate, as the right-half intermediate, as an example of isotopically labeled title compds., is given.

L10 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:686349 CAPLUS
DN 141:375677
TI The ion channel of F-ATP synthase is the target of toxic organotin compounds
AU von Ballmoos, Christoph; Brunner, Josef; Dimroth, Peter
CS ETH Zentrum, Institut fuer Mikrobiologie der Eidgenoessischen Technischen Hochschule, Zurich, CH-8092, Switz.
SO Proceedings of the National Academy of Sciences of the United States of America (2004), 101(31), 11239-11244
CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences
DT Journal
LA English
OS CASREACT 141:375677
AB ATP is the universal energy currency of living cells, and the majority of it is synthesized by the F1F0 ATP synthase. Inhibitors of this enzyme are therefore potentially detrimental for all life forms. Tributyltin chloride (TBT-Cl) inhibits ATP hydrolysis by the Na+-translocating ATP synthase of Ilyobacter tartaricus or the H+-translocating counterpart of Escherichia coli with apparent Ki of 200 nM. To target the site of this inhibition, we synthesized a tritium-labeled derivative of TBT-Cl in which one of the Bu groups was replaced by a photoactivatable aryldiazirine residue. Upon illumination, subunit a of the ATP synthase becomes specifically modified, and this labeling is suppressed in the presence of the original inhibitor. In case of the Na+ ATP synthase, labeling is also suppressed in the presence of Na+ ions, suggesting an interference in Na+ or TBT-Cl binding to subunit a. This interference is corroborated by the protection of ATP hydrolysis from TBT-Cl inhibition by 105 mM Na+. TBT-Cl strongly inhibits Na+ exchange by the reconstituted I. tartaricus ATP synthase. Taken together these results indicate that the subunit a ion channel is the target site for ATPase inhibition by toxic organotin compds. An inhibitor interacting specifically with this site has not been reported previously.
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:767857 CAPLUS
DN 141:410774
TI Synthesis and reactions of paramagnetic aromatic aldehydes as useful synthetic building blocks
AU Kalai, Tamas; Kulcsar, Gyozo; Jeko, Jozsef; Osz, Erzsebet; Hideg, Kalman
CS Institute of Organic and Medicinal Chemistry, University of Pecs, Pecs, 7602, Hung.
SO Synthesis (2004), (13), 2115-2120
CODEN: SYNTBF; ISSN: 0039-7881
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 141:410774
AB Starting from 2,2,5-trimethyl-2-(4-formylphenyl)pyrrolidin-1-yloxy, a paramagnetic benzaldehyde, a benzophenone-type photoactivable spin label, paramagnetic warfarin and phenindione were synthesized. Nitration of protected benzylic alc. led to 2-nitrobenzyl methanethiosulfonate, a thiol specific spin label, and 2-nitro aldehyde, which was a key compound for paramagnetic indigo, salicylic acid and nifedipine.
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

C:\Program Files\Stnexp\Queries\108162982.str



chain nodes :
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 42 43 44 45 46
ring nodes :
2 3 4 5 6 7 8 9 10 11 12 13 34 35 36 37 38 39 40 41
chain bonds :
2-43 3-44 6-8 9-14 11-15 12-16 16-17 17-18 18-19 19-20 20-21 20-22 22-23 23-24 24-25 25-26 26-27 27-28 28-29 28-30 30-31 31-32 32-33 33-36 40-42 44-45 45-46
ring bonds :
2-3 2-7 3-4 4-5 5-6 6-7 8-9 8-13 9-10 10-11 11-12 12-13 34-35 34-38 34-41 35-36 36-37 37-38 38-39 39-40 40-41
exact/norm bonds :
2-3 2-7 2-43 3-4 4-5 5-6 6-7 6-8 8-9 8-13 9-10 9-14 10-11 11-12 11-15 12-13 18-19 19-20 20-21 26-27 27-28 28-29 34-35 34-38 34-41 35-36 36-37 37-38 38-39 39-40 40-41 40-42 44-45 45-46
exact bonds :
3-44 12-16 16-17 17-18 20-22 22-23 23-24 24-25 25-26 28-30 30-31 31-32 32-33 33-36

G1:C,O,S,N

Match level :
2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS

```
=>
Uploading C:\Program Files\Stnexp\Queries\108162982.str

L11     STRUCTURE UPLOADED

=> d l11
L11 HAS NO ANSWERS
L11             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l11 full
FULL SEARCH INITIATED 20:17:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                    0 ANSWERS
SEARCH TIME: 00.00.01

L12           0 SEA SSS FUL L11
```

=>
Uploading C:\Program Files\Stnexp\Queries\108162983.str

L13 STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l13 full
FULL SEARCH INITIATED 20:18:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 60 TO ITERATE

100.0% PROCESSED 60 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L14 2 SEA SSS FUL L13

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	334.76	566.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-11.25

FILE 'CAPLUS' ENTERED AT 20:19:00 ON 14 DEC 2006

FILE COVERS 1907 - 14 Dec 2006 VOL 145 ISS 25
FILE LAST UPDATED: 13 Dec 2006 (20061213/ED)

=> s l14
L15 1 L14

=> d l15 bib abs hitstr

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:837304 CAPLUS
DN 141:296250
TI Preparation of nucleotide analogs with six membered rings and their incorporation into nucleic acids
IN Bergmann, Frank; Donner, Horst; Von der Eltz, Herbert; Heindl, Dieter; Herdewijn, Piet
PA Roche Diagnostics G.m.b.H., Germany; F.Hoffmann-La Roche A.-G.
SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1466919	A1	20041013	EP 2004-7907	20040401
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CA 2463719	AA	20041005	CA 2004-2463719	20040331
	US 2005004078	A1	20050106	US 2004-816298	20040401
	JP 2004339202	A2	20041202	JP 2004-110224	20040402
	CN 1569870	A	20050126	CN 2004-10045158	20040405
PRAI	EP 2003-7844	A	20030405		

OS MARPAT 141:296250
GI



I

AB Title compds. (I; L = linker; B = heterocyclic base; R1 = protecting

group, label solid phase, H; R2 = H, OR6; R3 = protecting group, linker covalently coupled to a solid phase, phosphoramidite, phosphonate, triphosphate; R4 = H, OH, alkyl, halo, OR5, SR5, NR5R5a, label linker covalently coupled to a solid phase; R6 = H, protecting group, linking moiety coupled to a solid phase, phosphoramidite, phosphonate; R5 = alkyl, alkenyl, alkynyl, aryl, acyl, protecting group, H; R5a, R5b = H, alkyl, alkenyl, alkynyl, aryl, acyl; Y = O, S, NR5, CR5aR5b; dotted line = optional double bond), were prepared Thus, 1,5-anhydro-2-(5-(6-biotin-amido-hexanoate amido-allyl)-uracil)-2,3-dideoxy-D-arabino-hexitol-6-triphosphate was prepared for incorporation into nucleic acids for use in PCR (polymerase chain reaction)-based diagnostics.

IT 764658-10-8P 764658-11-9P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of labeled nucleotides, capable of oligomerization, for uses in nucleic acid hybridization and PCR diagnostic studies)

RN 764658-10-8 CAPLUS

CN D-arabino-Hexitol, 1,5-anhydro-2,3-dideoxy-2-[5-[3-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]amino]-1-propenyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]-, 6-(tetrahydrogen triphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 764658-11-9 CAPLUS

CN D-Altritol, 1,5-anhydro-2-deoxy-2-[5-[3-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]amino]-1-propenyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]-, 6-(tetrahydrogen triphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



=>

```
=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        17.99     584.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -0.75     -12.00

FILE 'BIOSIS' ENTERED AT 20:35:58 ON 14 DEC 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 20:35:58 ON 14 DEC 2006

FILE 'CAPLUS' ENTERED AT 20:35:58 ON 14 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 20:35:58 ON 14 DEC 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 20:35:58 ON 14 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s (pyranosyl? or cyclohexenyl?) (4a) nucleoside?
L16         142 (PYRANOSYL? OR CYCLOHEXENYL?) (4A) NUCLEOSIDE?

=> s l16 and label? (4a) base?
L17           0 L16 AND LABEL? (4A) BASE?

=> s l16 and label?
L18           8 L16 AND LABEL?

=> dup rem l18
PROCESSING COMPLETED FOR L18
L19           8 DUP REM L18 (0 DUPLICATES REMOVED)

=> d l19 bib abs 1-8

L19  ANSWER 1 OF 8  USPATFULL on STN
AN     2005:17310  USPATFULL
TI     Oligomeric compounds for the modulation survivin expression
IN     Hansen, Bo, Copenhagen K, DENMARK
       Thrue, Charlotte Albaek, Copenhagen K, DENMARK
       Westergaard, Majken, Birkerod, DENMARK
       Petersen, Kamille Dumong, Lejre, DENMARK
       Wissenbach, Margit, Fredensborg, DENMARK
PI     US 2005014712       A1  20050120
AI     US 2004-776934      A1  20040210 (10)
PRAI   US 2003-446372P     20030210 (60)
       US 2003-523591P     20031119 (60)
DT     Utility
FS     APPLICATION
LREP   EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205
CLMN   Number of Claims: 152
ECL    Exemplary Claim: 1
DRWN   12 Drawing Page(s)
LN.CNT 11352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AB Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 8 USPATFULL on STN
AN 2004:315164 USPATFULL
TI Oligomeric compounds for the modulation of ras expression
IN Hansen, Bo, Copenhagen K, DENMARK
Thrue, Charlotte Albaek, Copenhagen K, DENMARK
Westergaard, Majken, Birkered, DENMARK
Petersen, Kamille Dumong, Lejre, DENMARK
Wissenbach, Margit, Fredensborg, DENMARK
PA Santaris Pharma A/S (non-U.S. corporation)
PI US 2004248840 A1 20041209
AI US 2004-776917 A1 20040210 (10)
PRAI DK 2003-1539 20031020
US 2003-446363P 20030210 (60)
DT Utility
FS APPLICATION
LREP Peter F. Corless, EDWARDS & ANGELL, LLP, P.O. Box 55874, Boston, MA, 02205
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras, expression of mutated Ha-ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 8 USPATFULL on STN
AN 2004:307046 USPATFULL
TI Oligomeric compounds for the modulation of thioredoxin expression
IN Hansen, Bo, Copenhagen K, DENMARK
Thrue, Charlotte Albaek, Copenhagen K, DENMARK
Westergaard, Majken, Birkered, DENMARK
Petersen, Kamille Dumong, Lejre, DENMARK
Wissenbach, Margit, Fredensborg, DENMARK
PA Santaris Pharma A/S (non-U.S. corporation)
PI US 2004241717 A1 20041202
AI US 2004-776933 A1 20040210 (10)
PRAI US 2003-446374P 20030210 (60)

DT Utility
FS APPLICATION
LREP Peter F. Corless, EDWARDS & ANGELL, LLP, P. O. Box 55874, Boston, MA, 02205
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3843
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligonucleotides directed against the TRX gene are provided for modulating the expression of TRX. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the TRX. Methods of using these compounds for modulation of TRX expression and for the treatment of diseases associated with either overexpression of TRX, expression of mutated TRX or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 4 OF 8 USPATFULL on STN
AN 2004:185060 USPATFULL
TI Modified nucleosides and nucleotides and use thereof
IN Chattopadhyaya, Jyoti, Uppsala, SWEDEN
PI US 2004142946 A1 20040722
AI US 2003-399951 A1 20030423 (10)
WO 2001-SE2484 20011109
DT Utility
FS APPLICATION
LREP YOUNG & THOMPSON, 745 SOUTH 23RD STREET 2ND FLOOR, ARLINGTON, VA, 22202
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 930
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to modified nucleotides and nucleosides and reagents to produce these. The modified nucleotides and nucleotides are assembled to larger oligonucleotides and oligonucleosides, which, for example, may be used for diagnostics of polymorphisms and for antisense therapy of various conditions. The oligonucleotides and oligonucleosides described in the invention have very good endonuclease resistance without compromising the RNA cleavage properties of RNase H wherein combinations of modifications with Y, Z, R or B are claimed: X=O or S, NH or NCH.sub.3, CH.sub.2 Or CH(CH.sub.3), Y=O, S, or NH or NCH.sub.3, CH.sub.2or CH(CH.sub.3); Z=O, S, or NH or NCH.sub.3, CH.sub.2 or CH(CH.sub.3); R=O or S, or NH or NCH.sub.3, CH.sub.2 or CH(CH.sub.3); B=A, C, G, T; 5-F/cl/BrU or --C, 6-thioguanine, 7-deazaguanine; α- or β-D- (or L)ribo, xylo, arabino or lyxo configuration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 8 USPATFULL on STN
AN 2003:234845 USPATFULL
TI Method for producing a pyranosyl nucleic acid conjugate
IN Miculka, Christian, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Windhab, Norbert, Hattersheim, GERMANY, FEDERAL REPUBLIC OF
Brandstetter, Tilmann, Munchen, GERMANY, FEDERAL REPUBLIC OF
Burdinski, Gerhard, Nastatten, GERMANY, FEDERAL REPUBLIC OF
PA Nanogen Recognomics GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PI US 6613894 B1 20030902
WO 9915540 19990401
AI US 2000-509010 20000320 (9)
WO 1998-EP5998 19980921
PRAI DE 1997-19741715 19970922
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Crane, L. Eric
LREP O'Melveny & Myers LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1940
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a process for the preparation of a pyranosyl nucleic acid of the formula (I) or of the formula (II) ##STR1##

The process for the preparation of the pyranosyl nucleic acid comprises (a) bonding the nucleoside to a solid support, (b) deprotecting the 3',4'-protected nucleoside, (c) reacting the reaction product from step (b) with a 3',4'-protected pyranosyl nuceloside phosphoramidite, repeating steps (b) and (c) one or more times to produce the desired length of nucleic acid, and coupling a biomolecule to the product of step (d). In a further step, the nucleic acid can be released from the solid support. In one embodiment, the biomolecule may be a DNA or RNA, where furanosyl nucleoside phosphoramidites are added to the pyranosyl nucleic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 8 USPATFULL on STN
AN 2001:223894 USPATFULL
TI Methods, procedures, and formats for using microelectronic array devices to perform multiplex immunoassay analyses
IN Windhab, Norbert, Hofheim, Germany, Federal Republic of
Heller, Michael J., Encinitas, CA, United States
Anderson, Richard R., Encinitas, CA, United States
Fiechtner, Michael D., Poway, CA, United States
Nova, Tina S., Rancho Santa Fe, CA, United States
Schweitzer, Markus, Frankfurt am Main, Germany, Federal Republic of
Sundquist, Alfred R., San Diego, CA, United States
Brucher, Christoph, Sulzbach, Germany, Federal Republic of
Orwick, Jill M., San Diego, CA, United States
Muller, Jochen, Diez, Germany, Federal Republic of
Raddatz, Stefan, Wiesbaden, Germany, Federal Republic of
Ackley, Donald E., Cardiff, CA, United States
Hamon, Christian, Frankfurt am Main, Germany, Federal Republic of
PI US 2001049111 A1 20011206
AI US 2001-783763 A1 20010214 (9)
RLI Continuation-in-part of Ser. No. US 1999-374338, filed on 13 Aug 1999, PENDING
DT Utility
FS APPLICATION
LREP LYON & LYON LLP, 633 WEST FIFTH STREET, SUITE 4700, LOS ANGELES, CA, 90071
CLMN Number of Claims: 112
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 2862
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to devices and methods for carrying out multi-step and multiplex immunoaffinity binding reactions in microscopic formats. In particular, these devices and methods allow the user to rapidly carry out multiple immunoassays in the same sample volume, and

to rapidly resolve the results of those immunoassays in an electronically assisted format. The assays may be further multiplexed in that several samples may be analyzed and visualized on the same microelectronic array. In addition, the methods and procedures of the invention allow the use of electronic stringency to further improve the specificity and accuracy of the immunoassays on the microelectronic array devices

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:395021 CAPLUS
DN 131:116450
TI Pyranosyl-RNA supramolecules containing non-hydrogen-bonding base-pairs
AU Hamon, Christian; Brandstetter, Tilmann; Windhab, Norbert
CS Department Bio-Organic Systems, Aventis Research Technologies, Frankfurt/Main, D-65926, Germany
SO Synlett (1999), (Spec.), 940-944
CODEN: SYNLES; ISSN: 0936-5214
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 131:116450
AB Synthesis and properties of a pyranosyl-RNA nucleoside using tryptamine as nucleobase is reported. Incorporation of this unit into oligomers using standard phosphoamidite chemical yielded self-complementary and non-selfcomplementary oligonucleotide pairs. Thermal melting expts. of these examples showed the sequence-dependent stabilizing characteristics of the incorporated base in the sym. pairing constitution with a standard Tm near that of a similar A-T-pair as well as pairing selectivity with respect to non-sym. pairing tolerating thymine, but destabilizing if confronted to an adenine as complementary base in the antiparallel strand.
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 8 USPATFULL on STN
AN 1998:82883 USPATFULL
TI Antisense oligomers
IN Goodnow, Jr., Robert Alan, Basking Ridge, NJ, United States
Tam, Steve Yik-Kai, West Caldwell, NJ, United States
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US 5780607 19980714
AI US 1996-727685 19961008 (8)
PRAI US 1995-5689P 19951013 (60)
US 1996-22484P 19960809 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Marschel, Ardin H.; Assistant Examiner: Riley, Jezia
LREP Johnston, George W., Tramaloni, Dennis P., Kirk, Jr., Joseph P.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1856
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Antisense oligomers of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.4 are independently hydrogen, lower alkyl or acyl;

R.sub.3 is hydrogen or lower alkyl;

B is a nucleobase or a protected nucleobase, such that said oligomer has a sequence of bases complementary to a selected RNA;

n is 5 to 30;

X is NR.sub.3 R.sub.4 ;

Y is OR.sub.3, or NHR.sub.3 ;

as well as, pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.